![\"Flightpath](\"https:\/\/www.send2press.com\/wire\/images\/21-0209s2p-flightpath-bio-696x522.jpg\")
<\/em><\/p>\n- \n
- Flightpath is led by an experienced team eager to execute deep data discovery and drive a pipeline of narrow-spectrum, targeted therapeutics into the clinic<\/li>\n
- Company aims to combine deep genomic sequencing, metabolomics and immune-cell profiling with next generation machine-learning approaches to solve multiple pathogen-driven diseases and syndromes<\/li>\n
- Company seeks to expand team to support operational acceleration and development efforts<\/li>\n<\/ul>\n
\u201cToday, more than ever, we understand that pathogen-driven epidemics like Lyme disease need to be more easily and accurately diagnosed and more specifically treated with narrow-spectrum, targeted therapies to avoid the microbiome damage that occurs with broad-spectrum antibiotics,\u201d said Matt Tindall, Flightpath Co-founder and CEO.<\/p>\n
Of the 476K patients diagnosed with acute Lyme disease each year in the U.S., most are treated with broad-spectrum antibiotics, but 10 to 20% endure debilitating symptoms such as fatigue, neurological complications, and myalgias after treatment, a condition known as Persistent Lyme disease (PLD). The etiology of PLD is not understood, and objective diagnostic tools are lacking.<\/p>\n
Interestingly, PLD symptoms overlap several diseases in which patients exhibit alterations in their microbiome. In a recent study, published in mBio (September 2020), Lewis et al determined that microbiome sequencing data alone were indicative of late-stage Lyme disease, which presents a potential, novel diagnostic tool for PLD.<\/p>\n
The authors found that patients with post-treatment Lyme disease syndrome, a subset of PLD, had a distinct microbiome signature, allowing for an accurate classification of over 80% of analyzed cases. Importantly, this signature supports the validity of PLD and is the first potential biological diagnostic tool for the disease.<\/p>\n
\u201cOur ability to analyze the microbiome, transcriptome and metabolome and identify disease signatures will give us new tools to unlock the potential of microbiome-based medicines in rare infectious diseases and potentially pathogen-driven cancers,\u201d said Mark de Souza, Flightpath Co-founder and Executive Chairman. \u201cWe\u2019re excited to get to work with the Illumina team and our world-class lab and academic partners to tackle this disease area with fresh perspectives, novel approaches and new data.\u201d<\/p>\n
About Flightpath Biosciences<\/strong><\/p>\n
Flightpath Biosciences is developing microbiome-targeted therapeutics and advanced biomarker-based diagnostics for the treatment of infectious diseases. Flightpath\u2019s mission is to transform patient\u2019s lives with medicines developed using a multidisciplinary approach to human and pathogen biology.<\/p>\n
Please visit\u00a0us at https:\/\/flightpath.bio\/<\/a> and on Twitter at\u00a0https:\/\/twitter.com\/FlightpathB<\/a> for more information.<\/p>\n
Media Contact:
\nMichael Bellas
\n\u202a(510) 859-8668
\nhttps:\/\/flightpath.bio\/contact-us\/<\/a><\/p>\n
![https:\/\/www.Send2Press.com\/300dpi\/21-0209s2p-flightpath-300dpi.jpg<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"BERKELEY, Calif., Feb. 9, 2021 (SEND2PRESS NEWSWIRE) — Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator’s second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD).<\/p>\n","protected":false},"author":8811,"featured_media":68281,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[499,12804,15336,602,1,10,61,559],"tags":[15339,15337,12946,15338],"class_list":["post-68328","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medical-research-news","category-ap","category-berkeley","category-biotechnology-news","category-business-news","category-california-news","category-health-medical-news","category-products-news","tag-biomarker-based-diagnostics","tag-illumina-accelerator","tag-lyme-disease","tag-persistent-lyme-disease","has-post-title","has-post-date","no-post-category","no-post-tag","no-post-comment","has-post-author"],"acf":[],"views":6297,"_links":{"self":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/68328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/users\/8811"}],"replies":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/comments?post=68328"}],"version-history":[{"count":0,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/68328\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media\/68281"}],"wp:attachment":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media?parent=68328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/categories?post=68328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/tags?post=68328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}](\"https:\/\/www.Send2Press.com\/300dpi\/21-0209s2p-flightpath-300dpi.jpg\"){kind=link}